PLUR: Pluri Inc. Stock

by  •  • Comments Off on PLUR: Pluri Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 41.72
Enterprise Value ($M) 63.40
Book Value ($M) -2.92
Book Value / Share -0.37
Price / Book -14.30
NCAV ($M) -11.41
NCAV / Share -1.46
Price / NCAV -3.66

Profitability (mra)
Return on Invested Capital (ROIC) -0.75
Return on Assets (ROA) -0.55
Return on Equity (ROE) -10.76

Liquidity (mrq)
Quick Ratio 5.04
Current Ratio 5.04

Balance Sheet (mrq) ($M)
Current Assets 22.37
Assets 30.86
Liabilities 33.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13D Chutzpah Holdings Ltd

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER S
2025-02-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT UNDE
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UND
2024-09-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-13 1,632 6,917 23.59
2025-05-12 3,940 48,586 8.11
2025-05-09 9,156 39,229 23.34
2025-05-08 1,374 8,585 16.00

(click for more detail)

Similar Companies
PCSA – Processa Pharmaceuticals, Inc. PDSB – PDS Biotechnology Corporation
PHIO – Phio Pharmaceuticals Corp. PMCB – PharmaCyte Biotech, Inc.
PMN – ProMIS Neurosciences, Inc.


Financial data and stock pages provided by
Fintel.io